MET and neoplasm: Capmatinib prevents c-Met-mediated phosphorylation of downstream signaling proteins as well as the proliferation and survival of c-Met-dependent tumor cells by inhibiting the phosphorylation of both wild-type and mutant variants of c-Met—a process triggered by the binding of its endogenous ligand, hepatocyte growth factor.